Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.06+0.02 (+1.92%)
Close on Nov 17, 2026Market cap $106.36MP/E –Yield –
Cellectis price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Cellectis's price to sales ratio was 1.9× on Nov 11, 2026, against 12.3× a year earlier. Over the last 5 years it ranged from 1.5× to 76.5×, with a median of 5.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.9× | −9.8 |
| 2025 | Dec 31, 2025 | 11.7× | +4.6 |
| 2024 | Jan 31, 2024 | 7.1× | −0.2 |
| 2023 | Dec 29, 2023 | 7.3× | +4.2 |
| 2022 | Dec 30, 2022 | 3.1× | −4.1 |
| 2021 | Dec 31, 2021 | 7.2× | −68.5 |
| 2020 | Dec 31, 2020 | 75.7× | +18.6 |
| 2019 | Dec 31, 2019 | 57.1× | +33.3 |
| 2018 | Dec 31, 2018 | 23.8× | +0.8 |
| 2017 | Dec 29, 2017 | 23.0× | +12.3 |
| 2016 | Dec 30, 2016 | 10.7× | – |
See a number that looks wrong?